Lifecore has licensed the patented Corgel® BioHydrogel technology from the Cleveland Clinic. This biocompatible hyaluronan hydrogel is based on di-hydroxyphenyl linkages of tyramine substituted sodium hyaluronate (NaHy). Lifecore has completed ISO 10993 safety and toxicity studies on this technology.
Corgel® BioHydrogel has a wide range of physical properties depending on the tyramine substitution (TS) percentage and the tyramine substituted hyaluronan (TS-NaHy) concentration. Hydrogels formed from TS-NaHy solutions of 6.25 – 100 mg/mL display a spectrum of physical properties that include those of a weak gel, a paste, or a fractile solid.
For more information, please see the Instructions for Proper Use.
>Download Corgel BioHydrogel Kit Instructions
>Download Detailed Chemistry Description
Corgel® BioHydrogel can be formed under physiologic conditions. This allows for the direct inclusion of cells or bioactive agents prior to or during cross-linking. Alternatively, in situ cross-linking directly adjacent to living tissue can be done while maintaining cell and tissue viability. Because the degree of substitution required for using Corgel is very low (1% – 5%), much of the native sodium hyaluronate structure and behavior is maintained.
Both the functional groups, and the resulting cross-linked structures, have unique photometric properties that allow for evaluation of the degree of substitution and cross-linking.
POTENTIAL APPLICATIONS:
Corgel® BioHydrogel is only for research purposes, and not intended for human use.
Publications referencing Corgel®
General information on the FDA’s position on cell/scaffold products
General information discussing hyaluronan-based hydrogels
Corgel®BioHydrogel (TS-NaHy) technology is covered by US patents 6,982,298; 7,368,502; 7,465,766
Cleveland Clinic is a © of The Cleveland Clinic Foundation
Lifecore Biomedical and Corgel are trademarks of Lifecore Biomedical,